Articles related to SURGICAL ONCOLOGY

The study underscores the potential of perioperative durvalumab in combination with neoadjuvant chemotherapy to significantly improve event-free survival and pathological complete response in patients with resectable NSCLC.

Discover how local therapy options like radiotherapy and radical prostatectomy can significantly improve overall survival rates in cN1 prostate cancer patients.

Understanding the nuances in diagnosing soft tissue masses is crucial for healthcare providers, as misdiagnosis can lead to delays in treatment and potentially worsen patient outcomes.

Discover the key predictors of PSA persistence post-prostate cancer surgery and how they can inform your treatment plans and patient discussions.

Understanding the impact of lymphovascular invasion on overall survival in RCC patients is crucial for surgical decision-making and postoperative care.

From November 15, 2015, to March 9, 2021, scientists conducted an open-label, phase 3 randomized clinical trial at 17 Spanish centers to assess the efficacy and safety of intraoperative HIPEC in patients with locally advanced colon cancer. The primary outcome was the 3-year locoregional control (LC) rate, which was defined as the proportion of patients who did not have peritoneal disease recurrence after adjusting for intention to treat. Patients included ranged in age from 18 to 75 years old and had been diagnosed with locally advanced primary colon cancer prior to surgery. They discovered that combining HIPEC with complete surgical resection for locally advanced colon cancer enhanced the 3-year LC rate compared to surgery alone, and they recommend that this strategy be evaluated for patients with locally advanced colorectal cancer.